OKYO Pharma focuses on:
A novel class of membrane-anchored Chemerin receptor GPCR agonist that targets the inflammatory pathways to treat dry eye syndrome, uveitis and allergic conjunctivitis.
An agonist for MAS-Related G Protein-Coupled Receptor (MRGPR), a non-opioid analgesic, for ocular and chronic pain management using novel topical and nasal formulations.
Company Details
- Employees
- 6
- Founded
- -
- Address
- 55 Park Lane, London,england W1k 1qg,united Kingdom
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.okyopharma.com/
- HQ
- London, England
Okyo Pharma Questions
Okyo Pharma's website is https://www.okyopharma.com/
Okyo Pharma's LinkedIn profile is https://uk.linkedin.com/company/okyo-pharma
Okyo Pharma has
6 employees.
View email and phone details for 6
employees at Okyo Pharma.
Okyo Pharma's industry is
Biotechnology Research
Okyo Pharma's top competitors are
Glaukos Corporation,
Longeveron,
Eyenovia, Inc.,
Apellis Pharmaceuticals,
Alzamend Neuro,
Tiziana Life Sciences,
Neurotech Pharmaceuticals, Inc.,
Lenz Therapeutics,
Ora,
Kaerus Bioscience Ltd..
Okyo Pharma's categories are Biotechnology Research
Okyo Pharma's founding year is 2018
